Chanca Piedra: History and Traditional Use

Few plant names are as vivid as chanca piedra — Spanish for "stone breaker." The small, weedy herb behind that name (Phyllanthus niruri) carries one of the most striking stories in ethnobotany: a plant that traditional healers on opposite sides of the world, working independently, settled on for the same handful of complaints — stones in the kidney and bladder, jaundice, and ailing livers. This article traces what is actually documented about that history, separates living folk tradition from the modern laboratory record, and is honest about where the evidence is strong, where it is thin, and where the popular story runs ahead of the science.

Table of Contents

  1. A Plant of Many Names
  2. The Stone-Breaker of the Amazon and South America
  3. Bhumyamalaki: the Ayurvedic Tradition of India
  4. Chinese, Caribbean, and African Folk Use
  5. Botany and How the Plant Was Catalogued
  6. From Folklore to the Laboratory
  7. The Hepatitis B Story
  8. The Kidney-Stone Trials
  9. What This History Does and Does Not Mean
  10. Research Papers and References
  11. Connections
  12. Featured Videos

A Plant of Many Names

The name most people know it by, chanca piedra, is Spanish and translates literally as "stone breaker" or "shatter stone." It is one of those folk names that doubles as a claim: the herb earned it because South American healers used it for people trying to pass kidney and bladder stones. In Brazil the very same idea is preserved in the Portuguese names quebra-pedra and arranca-pedras ("break-stone" and "pull-out-stones"), and in English-language commerce the plant is sold straightforwardly as stonebreaker. None of these names is a modern marketing invention; they are the traditional names of the plant in the regions where it grows, and the consistency of the "stone" theme across languages is itself a piece of historical evidence.

A second cluster of names describes what the plant looks like rather than what it does. The tiny seed capsules sit in a neat row along the underside of each leafy branchlet, which gave rise to the English nickname seed-under-leaf and, in Tamil, to keezhanelli (also written kizhanelli), roughly "the nelli that grows low to the ground." The Sanskrit and Hindi name bhumyamalaki or bhumi amla — "earth gooseberry" or "ground amla" — reflects the traditional observation that this little plant shares medicinal qualities with the much larger amla tree (Phyllanthus emblica, Indian gooseberry), to which it is botanically related. In Traditional Chinese sources the plant has been called ye xia zhu, commonly rendered "pearl under the leaf," again pointing to those characteristic seed capsules.

Taken together this thicket of names tells us something before we read a single research paper: Phyllanthus niruri was familiar enough, widespread enough, and useful enough that nearly every culture that lived alongside it gave it a name encoding either its appearance or its reputed power over stones, jaundice, and the liver. That cross-cultural familiarity is the backdrop to everything that follows.

Back to Table of Contents

The Stone-Breaker of the Amazon and South America

The herb's best-known traditional home is the Amazon basin and the wider tropics of South America, where it grows as a common weed of disturbed ground, gardens, and roadsides. Tropical-plant and ethnobotanical references record that across Peru, Brazil, and the Guianas the whole plant has long been brewed as a decoction (a simmered water extract) and given to people passing kidney and bladder stones, for painful or difficult urination, for jaundice, and to support the liver. The same sources document a much broader folk repertoire in different regions — the plant has been used traditionally for colic, fevers, flu, malaria, dysentery, diabetes, and a range of genitourinary complaints — but the thread that runs through nearly every account, and the one that gave the plant its name, is its reputation against stones.

It is important to be careful about how old this tradition is, because the popular literature is not. Many websites and product pages assert that Amazonian peoples have used chanca piedra "for hundreds of years" or specifically "for over five hundred years." That broad claim is plausible — the plant is native, abundant, and deeply embedded in regional folk medicine — but the careful ethnobotanical references that document these uses do not attach a firm first-use date or name an individual discoverer, and indigenous oral medical traditions generally predate any written record of them. The honest statement is this: chanca piedra has a long, well-attested history in South American folk medicine, traditionally as a stone-breaking and liver-supporting plant, but no single person "invented" the remedy and no precise founding date can be documented. It emerged, as most folk medicines did, from generations of accumulated practice.

What can be said with more confidence is when the modern chapter began. It was Brazilian researchers, drawing directly on this folk reputation, who in the 1980s and 1990s first brought Phyllanthus niruri into the laboratory and the clinic to test the stone-breaker claim — work taken up in the sections below. In other words, the tradition came first and posed the question; the science arrived centuries later to examine it.

Back to Table of Contents

Bhumyamalaki: the Ayurvedic Tradition of India

On the other side of the world, the very same species is one of the classic liver herbs of Ayurveda, the traditional medical system of the Indian subcontinent, where it is known as bhumyamalaki (bhumi amla). In Ayurvedic practice it is described as a bitter, cooling, pitta-pacifying herb used chiefly for kamala — the classical category that includes jaundice and liver disorders — and for urinary complaints and disorders of the blood. Modern Ayurvedic reviews and practitioners also list it for cough, anemia, skin disorders, and as a general liver tonic, frequently combining it with other hepatic herbs.

As with the Amazonian record, the antiquity of this use deserves an honest hedge. Ayurvedic and herbal sources commonly say bhumyamalaki has been used "for over two thousand years" and attribute it to the foundational Sanskrit medical compendia, the Charaka Samhita and the Sushruta Samhita. Ayurveda is unquestionably an ancient, continuously practised tradition, and bhumyamalaki is a long-standing part of its materia medica; that much is well supported. But readers should know that linking a specific modern botanical species to a specific verse in a two-thousand-year-old Sanskrit text is genuinely difficult — classical plant names do not map cleanly onto modern Linnaean species, several related Phyllanthus plants share the same vernacular names, and precise textual attributions vary between secondary sources. So this page treats the Ayurvedic use of bhumyamalaki as a genuine and old tradition for the liver and urinary tract, while declining to pin it to an exact date or chapter that cannot be firmly verified.

What is striking, and historically real, is the convergence: Ayurvedic healers in India and Amazonian healers in South America — with no contact between them — independently reached for the same small Phyllanthus herb for the same broad purposes, the liver and the urinary tract. That parallel discovery is one of the most interesting features of this plant's history.

Back to Table of Contents

Chinese, Caribbean, and African Folk Use

Phyllanthus niruri and its very close relatives grow throughout the warm regions of the world, and the folk-medical record follows the plant wherever it spread. In southern China and parts of Southeast Asia, plants of this group (under names such as ye xia zhu) have been used traditionally for what Chinese medicine frames as "damp-heat" conditions of the liver and the urinary tract — conceptually parallel to the jaundice-and-stones indications seen elsewhere. Comprehensive pharmacological reviews of the genus note that Phyllanthus species have been employed in folk medicine across most tropical and subtropical countries specifically for kidney and bladder disturbances, intestinal infections, diabetes, and hepatitis.

The herb also features in Caribbean, Central American, and West African ethnomedicine, where members of the genus appear in traditional remedies for fevers, digestive complaints, urinary problems, and liver disorders. Because several closely related species — notably Phyllanthus amarus and Phyllanthus urinaria — look similar, share many of the same active compounds, and are often called by the same local names, the traditional and even the scientific literature frequently treats them together. This is not sloppiness so much as a reflection of how the plants were actually used: as an interchangeable group of small, bitter, leaf-flower weeds reached for to cool the liver and ease the passing of water and stones. The practical consequence — that supplement labelling is genuinely confused about which species is in the bottle — is taken up on the companion Chanca Piedra hub.

Back to Table of Contents

Botany and How the Plant Was Catalogued

For all its folk fame, Phyllanthus niruri is a modest-looking plant: a small, erect, much-branched annual herb, usually under half a metre tall, with two ranks of small oblong leaflets along slender green branchlets that give the whole plant a fern-like look. The detail that names the entire genus is its flowering habit. The genus name Phyllanthus comes from the Greek phyllon ("leaf") and anthos ("flower"): in many species the tiny flowers, and then the seed capsules, are borne along what looks like the edge of a leaf — really a flattened, leaf-like branchlet — so the plant appears to flower and fruit directly from its leaves. In P. niruri the little greenish flowers and the round seed capsules line the underside of these branchlets, which is exactly the feature captured by the folk names "seed-under-leaf" and "pearl under the leaf."

The plant was brought into the formal system of scientific botany by the Swedish naturalist Carl Linnaeus, who described Phyllanthus niruri in his landmark Species Plantarum of 1753 — the work that anchors modern botanical naming — which is why the species is written with the authority "L." after its name (Phyllanthus niruri L.). The species epithet niruri is taken from a traditional South Asian name for the plant. Modern classifications place it in the family Phyllanthaceae (older texts list the genus under Euphorbiaceae, the spurge family, from which Phyllanthaceae was later separated). Naming the plant is the one part of this history that can be tied to a documented person and date: Linnaeus and 1753. Everything to do with its medicinal use belongs instead to the older, un-authored world of folk tradition.

Back to Table of Contents

From Folklore to the Laboratory

The modern scientific story of chanca piedra is largely a story of researchers taking these old folk claims at face value and asking whether they hold up. Two reputed traditional uses — against hepatitis and liver disease and against kidney stones — drew the most attention, and each produced a distinct and instructive body of work.

By the late twentieth century, comprehensive reviews of the genus were summarising a substantial chemistry: Phyllanthus plants contain lignans (such as phyllanthin and hypophyllanthin), flavonoids, hydrolysable tannins including the ellagitannin geraniin, and other compounds, and laboratory studies reported antiviral, hepatoprotective, and stone-related activities that plausibly underlie the traditional uses. João Calixto and colleagues' widely cited 1998 review in Medicinal Research Reviews, and the later ethnopharmacology reviews by Patel and colleagues (2011) and Lee and colleagues (2016), are the standard scholarly entry points; they explicitly frame their work as testing folk-medical reputations against modern evidence. The remarkable feature of this literature is how directly it grew out of tradition — the questions the scientists asked were, almost word for word, the claims the healers had been making.

The honest summary of where that effort landed is mixed, and the next two sections give the detail: the kidney-stone work has produced encouraging human trials, while the hepatitis B work began with a sensational result that later studies could not reliably reproduce.

Back to Table of Contents

The Hepatitis B Story

The single most famous moment in chanca piedra's modern history came in 1988, when S. P. Thyagarajan and colleagues at the University of Madras published a short paper in The Lancet reporting that a preparation of Phyllanthus amarus (the sister species, used interchangeably with P. niruri) had a dramatic effect in carriers of the hepatitis B virus. In their preliminary trial, 22 of 37 treated carriers (about 59%) had lost the hepatitis B surface antigen — a key marker of active infection — when retested shortly after a 30-day course, compared with just 1 of 23 in the placebo group. For a virus with no good treatment at the time, this was an electrifying result, and it launched Phyllanthus into international attention as a possible natural antiviral.

The crucial part of the history, and the part most often left out of promotional accounts, is what happened next: the spectacular result did not reliably reproduce. Several follow-up trials over the following years reported much weaker effects or none at all. In one representative example, Doshi and colleagues published a two-stage trial in the Indian Journal of Gastroenterology in 1994 in which none of the 30 asymptomatic carriers treated cleared the surface antigen. When the Cochrane Collaboration — the international gold standard for evidence reviews — pooled the randomised trials in 2011 (Xia and colleagues), it concluded that there was no convincing evidence that Phyllanthus, compared with placebo, benefits people with chronic hepatitis B, while noting some possible modest benefit when combined with conventional antiviral drugs and calling, as such reviews almost always do, for larger and better trials.

This arc — a stunning early finding, a string of disappointing replications, and a cautious systematic review — is one of the most useful lessons in the whole field of herbal medicine. It does not prove the herb is worthless; the laboratory antiviral mechanisms are real and research continues. But it is a clear warning against building confidence on a single dramatic study, and it is the reason responsible sources today describe chanca piedra as, at most, a possible adjunct for liver health — never a substitute for proven antiviral therapy. The clinical detail is covered in the companion Liver Protection article.

Back to Table of Contents

The Kidney-Stone Trials

The plant's namesake use — breaking stones — has fared better under testing, though with an important correction to the folklore. Laboratory work by Brazilian groups, notably Marcio Barros, Nestor Schor, and Mirian Boim, showed in the early 2000s that an aqueous extract of Phyllanthus niruri interferes with the way calcium-oxalate crystals (the commonest kidney-stone material) form and clump together, and that in a rat model it reduced the number and weight of experimentally induced stones. The mechanism is best described not as literally dissolving a stone but as making it harder for crystals to assemble and grow, and altering the surface of crystals so they are smaller and more easily flushed out — an "anti-crystallization" effect rather than a chemical solvent.

Two human studies are the ones most often cited. In 2004, Nishiura and colleagues randomised calcium-stone-forming patients to P. niruri or placebo for three months and found that the herb helped normalise elevated urinary calcium — a genuine, if modest, shift in stone-promoting chemistry. In 2006, Micali and colleagues, publishing in The Journal of Urology, gave a P. niruri extract to patients after shock-wave lithotripsy (the standard procedure that breaks stones with sound waves) and reported a higher clearance of fragments, with the benefit reaching statistical significance specifically for stones in the hard-to-clear lower part of the kidney (a stone-free rate of about 94% with the herb versus 71% without). These are small studies, but they point in the same direction the tradition always claimed: the herb seems to help the body keep stones from forming and to pass fragments more easily. The practical protocol is detailed in the companion Kidney Stones article.

Back to Table of Contents

What This History Does and Does Not Mean

It is worth being plain about what this long history adds up to, because real people with kidney stones, hepatitis, or liver trouble read pages like this one. The history of chanca piedra is a genuinely impressive example of parallel folk discovery: cultures in the Amazon, in India, in China, in the Caribbean, and in West Africa, with no contact between them, independently chose the same small leaf-flower weed for stones, jaundice, and the liver. That convergence is real, it is well documented, and it is exactly the kind of signal that has, again and again, pointed scientists toward plants worth studying.

But a long tradition is a reason to investigate a remedy, not proof that it works. The modern record on chanca piedra is honestly mixed: encouraging human evidence for helping prevent stones and pass fragments after lithotripsy; a once-famous hepatitis B result that later trials and a Cochrane review could not confirm; and a great deal of promising but preliminary laboratory work on its other reputed effects. None of it makes the herb a cure for any serious disease. Anyone with a large or obstructing stone, with hepatitis, or with significant liver disease needs proper medical diagnosis and treatment — chanca piedra, where it has a place at all, is a gentle traditional support to be used alongside that care and discussed with a clinician, especially because it can interact with several medications. Understood that way — as a well-travelled folk remedy whose best claims are now being tested rather than as a miracle — the history of the stone-breaker is genuinely worth knowing.

Back to Table of Contents

Research Papers and References

The references below are the peer-reviewed reviews and clinical studies that document chanca piedra's traditional uses and the modern testing of them. Author names, titles, and journals are given as plain text; only stable identifiers (DOI or PubMed) are hyperlinked and open in a new tab. Classical traditional sources (the Sanskrit Ayurvedic compendia, and the regional folk pharmacopoeias of the Amazon, China, the Caribbean, and West Africa) are described in the article as living traditions rather than cited as modern papers, because specific species-and-date attributions to ancient texts cannot be reliably verified.

  1. Calixto JB, Santos AR, Cechinel Filho V, Yunes RA. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Medicinal Research Reviews. 1998;18(4):225-258. — PMID: 9664291
  2. Patel JR, Tripathi P, Sharma V, Chauhan NS, Dixit VK. Phyllanthus amarus: ethnomedicinal uses, phytochemistry and pharmacology: a review. Journal of Ethnopharmacology. 2011;138(2):286-313. — doi:10.1016/j.jep.2011.09.040
  3. Lee NYS, Khoo WKS, Adnan MA, Mahalingam TP, Fernandez AR, Jeevaratnam K. The pharmacological potential of Phyllanthus niruri. Journal of Pharmacy and Pharmacology. 2016;68(8):953-969. — doi:10.1111/jphp.12565
  4. Thyagarajan SP, Subramanian S, Thirunalasundari T, Venkateswaran PS, Blumberg BS. Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. The Lancet. 1988;2(8614):764-766. — PMID: 2901611
  5. Doshi JC, Vaidya AB, Antarkar DS, Deolalikar R, Antani DH. A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen. Indian Journal of Gastroenterology. 1994;13(1):7-8. — PMID: 8119752
  6. Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews. 2011;(4):CD008960. — doi:10.1002/14651858.CD008960.pub2
  7. Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N. Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urological Research. 2004;32(5):362-366. — doi:10.1007/s00240-004-0432-8
  8. Micali S, Sighinolfi MC, Celia A, De Stefani S, Grande M, Cicero AF, Bianchi G. Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. The Journal of Urology. 2006;176(3):1020-1022. — PMID: 16890682
  9. Barros ME, Schor N, Boim MA. Effects of an aqueous extract from Phyllanthus niruri on calcium oxalate crystallization in vitro. Urological Research. 2003;30(6):374-379. — doi:10.1007/s00240-002-0285-y
  10. Barros ME, Lima R, Mercuri LP, Matos JR, Schor N, Boim MA. Effect of extract of Phyllanthus niruri on crystal deposition in experimental urolithiasis. Urological Research. 2006;34(6):351-357. — doi:10.1007/s00240-006-0065-1

PubMed Topic Searches

  1. Phyllanthus niruri ethnobotany and traditional use — PubMed: Phyllanthus niruri ethnobotany traditional use
  2. Phyllanthus hepatitis B history of research — PubMed: Phyllanthus hepatitis B clinical trials

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents